Virus News and Research

Latest Virus News and Research

Novel hepatitis C-like virus discovered in dogs

In a study to be published online this week in the Proceedings of the National Academy of Sciences, researchers report the discovery of a novel hepatitis C-like virus in dogs. The identification and characterization of this virus gives scientists new insights into how hepatitis C in humans may have evolved and provides scientists renewed hope to develop a model system to study how it causes disease.

24 May 2011

Vertex Incivek receives FDA approval for treatment of chronic hepatitis C

The U.S. Food and Drug Administration today approved Incivek treat certain adults with chronic hepatitis C infection. Incivek is used for patients who have either not received interferon-based drug therapy for their infection or who have not responded adequately to prior therapies. Incivek is approved for use with interferon therapy made up of peginterferon alfa and ribavirin.

24 May 2011

Viewpoints: IPAB debate; Medicare flap continues; WSJ on VT single payer

While I applaud Ryan for getting the conversation started, I cannot support his specific plan — and therefore will vote "no" on his budget. Why can't I go along with the Ryan Medicare plan?

23 May 2011

Aethlon to introduce new adaptive dialysis-like affinity platform technology at C21 partnering conference

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announces that Chairman and CEO James A. Joyce will present the Aethlon ADAPT™ system in a presentation at the C21 BioVentures™ Life Sciences Partnering Conference.

23 May 2011

EDITORIAL: Study results show need for more data on HIV prevention economics

A recent study showing a "near-perfect way to halt sexual transmission of the AIDS virus has the potential to change the way international agencies and nations cope with the epidemic. But that can only happen if troubling issues of cost and practicality can be surmounted," a New York Times editorial says.

23 May 2011

Vertex receives FDA approval for INCIVEK to treat hepatitis C

Vertex Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration (FDA) has approved INCIVEK™ (telaprevir) tablets for a broad group of people with genotype 1 chronic hepatitis C with compensated liver disease (some level of damage to the liver but the liver still functions), including cirrhosis (scarring of the liver).

23 May 2011

Roche's new cobas TaqScreen MPX viral discriminatory test, v2.0 now available in Europe

Roche announced today that the cobas TaqScreen MPX Test, version 2.0 for use on the cobas s 201 system is now commercially available in Europe.

23 May 2011

Salk researchers successfully edit diseased gene in patient-specific induced pluripotent stem cells

In principle, genetic engineering is simple, but in practice, replacing a faulty gene with a healthy copy is anything but. Using mutated versions of the lamin A gene as an example to demonstrate the versatility of their virus-based approach, researchers at the Salk Institute for Biological Studies successfully edited a diseased gene in patient-specific induced pluripotent stem cells as well as adult stem cells.

21 May 2011

Coordinated efforts required to close gaps in preventive behavior: American Cancer Society

A new report from the American Cancer Society details cancer control efforts and outlines improvements as well as gaps in preventive behavior that contribute to cancer mortality.

21 May 2011

Merck's VICTRELIS receives European CHMP positive opinion for treatment of chronic HCV genotype 1 infection

Merck, today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion under accelerated assessment recommending approval of the investigational medicine VICTRELIS (boceprevir) for the treatment of chronic hepatitis C virus genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients with compensated liver disease who are previously untreated or who have failed previous therapy.

20 May 2011

Jennerex presents positive preliminary data from JX-594 Phase 2 trial for advanced liver cancer

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the design, development and commercialization of first-in-class targeted oncolytic products for cancer, today presented preliminary data from a randomized dose-ranging Phase 2 trial of JX-594 in patients with advanced liver cancer showing a benefit in overall survival for the high dose group.

20 May 2011

Medivir reports positive results from ASPIRE TMC435 phase 2b study for genotype 1 chronic hepatitis C

Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, today announced results from the ASPIRE phase 2b study that evaluates the addition of once daily TMC435 to pegylated interferon and ribavirin in patients with genotype 1 chronic hepatitis C whose prior treatment with pegylated-interferon (PegIFN) and ribavirin (RBV) was unsuccessful either because they relapsed, had a partial response or had a null response.

20 May 2011

Longer looks: Tough health care questions for GOP presidential contenders; Robotics help spike use of prostate treatment

For my money, the most interesting thing about Mitt Romney's health-care speech last week wasn't his struggle to defend Romneycare and distance it from Obamacare, but the largely hostile reception of the speech from the right.

20 May 2011

CEL-SCI initiates global Multikine Phase III trial for head and neck cancer in Russia

CEL-SCI Corporation announced today that it has commenced its global Phase III clinical trial for Multikine®, the Company's flagship immunotherapy, in Russia at the State Budgetary Healthcare Institution of Sverdlovsk Region - Sverdlovsk Regional Oncology Center in Ekaterinburg, Russia.

20 May 2011

CSL welcomes historic pandemic agreement

CSL Biotherapies welcomed news overnight of a decision by the World Health Assembly to adopt the Pandemic Influenza Preparedness Framework for the Sharing of Influenza Viruses and Access to Vaccines and Other Benefits. The Framework is the culmination of several years work by a dedicated working group of the World Health Organisation (WHO) and paves the way for greater global collaboration between public and private stakeholders in preparing the world for possible future influenza pandemics.

19 May 2011

Humanized BLT mice help prevent HIV/AIDS transmission

The more than 2.7 million new HIV infections recorded per year leave little doubt that the HIV/AIDS epidemic continues to spread globally. That's why there's the need for safe, inexpensive and effective drugs to successfully block HIV transmission.

19 May 2011

Abbott RealTime PCR assay for measuring HCV viral load receives FDA marketing approval

Abbott announced today that it has received approval from the U.S. Food and Drug Administration to market its RealTime PCR (polymerase chain reaction) test for measuring the viral load of hepatitis C (HCV), the leading cause of liver cancer in the United States.

19 May 2011

Epstein-Barr virus might cause multiple sclerosis, study confirms

The Epstein-Barr (EVB) virus -belonging to the herpesviruses family, which also includes the herpes simplex virus and the cytomegalovirus- is one of the environmental factors that might cause multiple sclerosis, a condition affecting the central nervous system, which causes are unknown.

18 May 2011

New experimental vaccine prevents infection of horses with deadly Hendra virus

CSIRO scientists have shown that a new experimental vaccine helps to protect horses against the deadly Hendra virus. Dr Deborah Middleton from CSIRO's Australian Animal Health Laboratory (AAHL) will announce the successful progress to develop the vaccine at the Australian Veterinary Association conference in Adelaide today.

18 May 2011

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Canada

CEL-SCI Corporation announced today that it has commenced its global Phase III clinical trial for Multikine, the Company's flagship immunotherapy, in Canada at St. Joseph's Healthcare - Hamilton, Ontario.

18 May 2011

Virus News and Research

Latest Virus News and Research

Novel hepatitis C-like virus discovered in dogs

Vertex Incivek receives FDA approval for treatment of chronic hepatitis C

Viewpoints: IPAB debate; Medicare flap continues; WSJ on VT single payer

Aethlon to introduce new adaptive dialysis-like affinity platform technology at C21 partnering conference

EDITORIAL: Study results show need for more data on HIV prevention economics

Vertex receives FDA approval for INCIVEK to treat hepatitis C

Roche's new cobas TaqScreen MPX viral discriminatory test, v2.0 now available in Europe

Salk researchers successfully edit diseased gene in patient-specific induced pluripotent stem cells

Coordinated efforts required to close gaps in preventive behavior: American Cancer Society

Merck's VICTRELIS receives European CHMP positive opinion for treatment of chronic HCV genotype 1 infection

Jennerex presents positive preliminary data from JX-594 Phase 2 trial for advanced liver cancer

Medivir reports positive results from ASPIRE TMC435 phase 2b study for genotype 1 chronic hepatitis C

Longer looks: Tough health care questions for GOP presidential contenders; Robotics help spike use of prostate treatment

CEL-SCI initiates global Multikine Phase III trial for head and neck cancer in Russia

CSL welcomes historic pandemic agreement

Humanized BLT mice help prevent HIV/AIDS transmission

Abbott RealTime PCR assay for measuring HCV viral load receives FDA marketing approval

Epstein-Barr virus might cause multiple sclerosis, study confirms

New experimental vaccine prevents infection of horses with deadly Hendra virus

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Canada

A new way of characterising biomolecules eBook

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Virus News and Research

Latest Virus News and Research

A new way of characterising biomolecules eBook

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Newsletters you may be interested in